IdentifySensors Biologics has developed a groundbreaking new technology that uses electronic nanosensors to detect the presence of COVID and other pathogens in saliva. This technology exists nowhere else on the market today, and Acclaim has driven the entire marketing and public relations campaign that has helped the company raise millions of dollars in investments and drive the product to commercialization.

Acclaim worked with IdentifySensors Biologics to develop extensive social media campaigns that drove millions of dollars in investments. The process began with a crowdfunding mechanism in cooperation with the SEC, while the investment relations team turned entry level investors to major investors .